Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
emjreviews.com10h
New Strategy Enhances PD-1 Therapy in Treatment-Resistant Cancers
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Pharmabiz20h
Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease
Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease: Tokyo Friday, February 21, 2025, 10:00 Hr ...
Targeted Oncology3d
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
The Pharma Letter1d
Chugai wins regulatory approval for Tecentriq for additional indication
Japanese drugmaker Chugai Pharmaceutical today announced gaining regulatory approval from the Ministry of Health, Labor and ...
Targeted Oncology1d
FDA Grants Breakthrough Therapy Status to Petosemtamab/Pembrolizumab in HNSCC
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
Merus’ petosemtamab granted Breakthrough Therapy designation by FDA
Merus (MRUS) announced that the FDA has granted Breakthrough Therapy designation to petosemtamab in combination with pembrolizumab for the ...
Pharmabiz1d
Merus’ petosemtamab receives US FDA breakthrough therapy designation for 1L PD-L1 positive head and neck squamous cell carcinoma
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...